Strategic expansion Verb Biotics recently launched Keystone Postbiotic and is actively partnering on probiotic strain development to enhance gut health solutions, signaling opportunities to position as a foundational microbiome ingredient provider for functional foods and dietary supplements.

Collaborative leverage The collaboration with Evogene to develop metabolite-producing probiotic strains indicates a channel for co-development opportunities and joint marketing with ingredient suppliers targeting precision health brands.

Acquisition assets Acquiring YSOPIA Bioscience’s strain library and IP assets expands Verb Biotics’ catalog and IP depth, enabling sales pitches around a broader and differentiated microbiome ingredient portfolio.

Funding credibility Completed Series A with $30M funding and ongoing preclinical data on Keystone Postbiotic enhances investor and buyer confidence, supporting conversations with mid-market CPG brands seeking proven microbiome solutions.

Market positioning As a B2B ingredient supplier serving food, beverage, and dietary supplement brands with pro, post, and synbiotics, Verb Biotics can target small-to-mid sized brands looking to scale microbiome claims, offering turnkey formulations and co-creation opportunities.